# RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

> **NCT00495378** · PHASE4 · TERMINATED · sponsor: **Ortho Biotech Products, L.P.** · enrollment: 25 (actual)

## Conditions studied

- Chemotherapy
- Cancer
- Anemia

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00495378
- **Lead sponsor:** Ortho Biotech Products, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2003-03
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** This study was stopped due to slow enrollment after enrolling 25 of 200 patients.
- **Last updated:** 2016-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495378, "RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00495378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*